

Janusz Rak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3790231/publications.pdf>

Version: 2024-02-01

108
papers

9,372
citations

50244

46
h-index

39638

94
g-index

109
all docs

109
docs citations

109
times ranked

12214
citing authors

#	ARTICLE	IF	CITATIONS
1	Coagulome and the tumor microenvironment: an actionable interplay. <i>Trends in Cancer</i> , 2022, 8, 369-383.	3.8	44
2	Cancer genetic alterations and risk of venous thromboembolism. <i>Thrombosis Research</i> , 2022, 213, S29-S34.	0.8	3
3	Blood coagulation and cancer genes. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101349.	0.7	9
4	Plasmonic nanobowtiefluidic device for sensitive detection of glioma extracellular vesicles by Raman spectrometry. <i>Lab on A Chip</i> , 2021, 21, 855-866.	3.1	36
5	Extracellular Vesicle Mediated Vascular Pathology in Glioblastoma. <i>Sub-Cellular Biochemistry</i> , 2021, 97, 247-273.	1.0	5
6	Selection of Fluorescent, Bioluminescent, and Radioactive Tracers to Accurately Reflect Extracellular Vesicle Biodistribution <i>in Vivo</i> . <i>ACS Nano</i> , 2021, 15, 3212-3227.	7.3	115
7	Isolation of Extracellular Vesicles for Proteomic Profiling. <i>Methods in Molecular Biology</i> , 2021, 2261, 193-206.	0.4	11
8	Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. <i>Blood Advances</i> , 2021, 5, 1682-1694.	2.5	46
9	Cancer genes and blood clots. <i>Blood</i> , 2021, 137, 1996-1997.	0.6	5
10	Nanofluidics for Simultaneous Size and Charge Profiling of Extracellular Vesicles. <i>Nano Letters</i> , 2021, 21, 4895-4902.	4.5	11
11	Oncogenic RAS drives the CRAF-dependent extracellular vesicle uptake mechanism coupled with metastasis. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12091.	5.5	15
12	Nanobowtie Embedded Microfluidic Device for SERS Identification of Extracellular Vesicles from Synthetic Liposomes. , 2021, , .		1
13	SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca ²⁺ flux to mitochondria. <i>Nature Communications</i> , 2021, 12, 5404.	5.8	20
14	Extracellular Vesicle Proteomes Shed Light on the Evolutionary, Interactive, and Functional Divergence of Their Biogenesis Mechanisms. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 734950.	1.8	7
15	Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5825.	1.7	7
16	Genetic and epigenetic regulation of cancer coagulome – lessons from heterogeneity of cancer cell populations. <i>Thrombosis Research</i> , 2020, 191, S99-S105.	0.8	14
17	Human multipotent mesenchymal stromal cells cytokine priming promotes RAB27B-regulated secretion of small extracellular vesicles with immunomodulatory cargo. <i>Stem Cell Research and Therapy</i> , 2020, 11, 539.	2.4	40
18	Extracellular vesicles from genetically unstable, oncogene-driven cancer cells trigger micronuclei formation in endothelial cells. <i>Scientific Reports</i> , 2020, 10, 8532.	1.6	18

#	ARTICLE	IF	CITATIONS
19	<sc>SMARCB1</sc> loss induces druggable cyclin <sc>D1</sc> deficiency via upregulation of <sc><i>MIR17HG</i></sc> in atypical teratoid rhabdoid tumors. <i>Journal of Pathology</i> , 2020, 252, 77-87.	2.1	11
20	Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. <i>Cancers</i> , 2020, 12, 618.	1.7	16
21	L(C3)icensing of exosomes for RNA export. <i>Nature Cell Biology</i> , 2020, 22, 137-139.	4.6	4
22	A reference map of the human binary protein interactome. <i>Nature</i> , 2020, 580, 402-408.	13.7	724
23	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 431-497.	1.0	11
24	Mapping Subpopulations of Cancer Cell-Derived Extracellular Vesicles and Particles by Nano-Flow Cytometry. <i>ACS Nano</i> , 2019, 13, 10499-10511.	7.3	148
25	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. <i>Nature Communications</i> , 2019, 10, 558.	5.8	76
26	SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. <i>Nature Communications</i> , 2019, 10, 557.	5.8	125
27	Oncogenes and Clotting Factors: The Emerging Role of Tumor Cell Genome and Epigenome in Cancer-Associated Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 373-384.	1.5	33
28	Extracellular Vesicles as Conduits of Non-Coding RNA Emission and Intercellular Transfer in Brain Tumors. <i>Non-coding RNA</i> , 2019, 5, 1.	1.3	48
29	Oncogenic Regulation of Extracellular Vesicle Proteome and Heterogeneity. <i>Proteomics</i> , 2019, 19, e1800169.	1.3	27
30	Age-related variations in gene expression patterns of renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 166-175.	0.8	8
31	Leukobiopsy – A Possible New Liquid Biopsy Platform for Detecting Oncogenic Mutations. <i>Frontiers in Pharmacology</i> , 2019, 10, 1608.	1.6	6
32	Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. <i>Neuro-Oncology</i> , 2018, 20, 236-248.	0.6	103
33	Leukocytes as a reservoir of circulating oncogenic DNA and regulatory targets of tumor-derived extracellular vesicles. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1800-1813.	1.9	49
34	Molecular subtypes and differentiation programmes of glioma stem cells as determinants of extracellular vesicle profiles and endothelial cell-stimulating activities. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1490144.	5.5	49
35	The Impact of Oncogenic EGFRvIII on the Proteome of Extracellular Vesicles Released from Glioblastoma Cells. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 1948-1964.	2.5	116
36	Cell Surface GRP78. , 2018, , 63-85.		4

#	ARTICLE	IF	CITATIONS
37	Single cell coagulomes as constituents of the oncogene-driven coagulant phenotype in brain tumours. <i>Thrombosis Research</i> , 2018, 164, S136-S142.	0.8	20
38	Extracellular vesicle communication pathways as regulatory targets of oncogenic transformation. <i>Seminars in Cell and Developmental Biology</i> , 2017, 67, 11-22.	2.3	105
39	Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. <i>Journal of Biological Chemistry</i> , 2017, 292, 21180-21192.	1.6	17
40	Inhibition of tissue factor signaling in breast tumour xenografts induces widespread changes in the microRNA expression profile. <i>Biochemical and Biophysical Research Communications</i> , 2017, 494, 700-705.	1.0	8
41	Mek activity is required for ErbB2 expression in breast cancer cells detached from the extracellular matrix. <i>Oncotarget</i> , 2017, 8, 105383-105396.	0.8	2
42	Oncosomes – large and small: what are they, where they came from?. <i>Journal of Extracellular Vesicles</i> , 2016, 5, 33109.	5.5	133
43	Biological basis of personalized anticoagulation in cancer: oncogene and oncomir networks as putative regulators of coagulopathy. <i>Thrombosis Research</i> , 2016, 140, S37-S43.	0.8	18
44	Studies on the Tumor Vasculature and Coagulant Microenvironment. <i>Methods in Molecular Biology</i> , 2016, 1458, 39-58.	0.4	3
45	Comparative transcriptomic analysis of human and Drosophila extracellular vesicles. <i>Scientific Reports</i> , 2016, 6, 27680.	1.6	42
46	Extracellular Vesicles in Brain Tumor Progression. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 383-407.	1.7	71
47	Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells. <i>American Journal of Pathology</i> , 2016, 186, 446-459.	1.9	32
48	PML – RAR α modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells. <i>Angiogenesis</i> , 2016, 19, 25-38.	3.7	35
49	Barriers to horizontal cell transformation by extracellular vesicles containing oncogenic H-ras. <i>Oncotarget</i> , 2016, 7, 51991-52002.	0.8	72
50	Oncogene-dependent survival of highly transformed cancer cells under conditions of extreme centrifugal force – implications for studies on extracellular vesicles. <i>Cellular and Molecular Biology Letters</i> , 2015, 20, 117-29.	2.7	2
51	An electrochemical clamp assay for direct, rapid analysis of circulating nucleic acids in serum. <i>Nature Chemistry</i> , 2015, 7, 569-575.	6.6	234
52	Extracellular vesicles, tissue factor, cancer and thrombosis – discussion themes of the ISEV 2014 Educational Day. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 26901.	5.5	69
53	Extracellular vesicles in the biology of brain tumour stem cells – Implications for inter-cellular communication, therapy and biomarker development. <i>Seminars in Cell and Developmental Biology</i> , 2015, 40, 17-26.	2.3	86
54	Inhibition of Oncogenic Epidermal Growth Factor Receptor Kinase Triggers Release of Exosome-like Extracellular Vesicles and Impacts Their Phosphoprotein and DNA Content. <i>Journal of Biological Chemistry</i> , 2015, 290, 24534-24546.	1.6	99

#	ARTICLE	IF	CITATIONS
55	Organ-seeking vesicles. <i>Nature</i> , 2015, 527, 312-314.	13.7	34
56	Anthracycline-containing chemotherapy causes long-term impairment of mitochondrial respiration and increased reactive oxygen species release in skeletal muscle. <i>Scientific Reports</i> , 2015, 5, 8717.	1.6	59
57	Genetic Basis of Thrombosis in Cancer. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 284-295.	1.5	19
58	Brain Neoplasms and Coagulation—Lessons from Heterogeneity. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0030.	0.4	19
59	The contribution of tumor and host tissue factor expression to oncogene-driven gliomagenesis. <i>Biochemical and Biophysical Research Communications</i> , 2014, 454, 262-268.	1.0	21
60	Ageing-related responses to antiangiogenic effects of sunitinib in atherosclerosis-prone mice. <i>Mechanisms of Ageing and Development</i> , 2014, 140, 13-22.	2.2	10
61	Oncogenic ras-driven cancer cell vesiculation leads to emission of double-stranded DNA capable of interacting with target cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 451, 295-301.	1.0	159
62	Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3544-3549.	3.3	90
63	Oncogenes and the coagulation system—forces that modulate dormant and aggressive states in cancer. <i>Thrombosis Research</i> , 2014, 133, S1-S9.	0.8	54
64	Qualitative changes in the proteome of extracellular vesicles accompanying cancer cell transition to mesenchymal state. <i>Experimental Cell Research</i> , 2013, 319, 2747-2757.	1.2	71
65	Impact of host ageing on the metastatic phenotype. <i>Mechanisms of Ageing and Development</i> , 2013, 134, 118-129.	2.2	8
66	Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours. <i>Proteomics</i> , 2013, 13, 1595-1607.	1.3	26
67	Brain Neoplasms and Coagulation. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 881-895.	1.5	38
68	Extracellular Vesicles—Biomarkers and Effectors of the Cellular Interactome in Cancer. <i>Frontiers in Pharmacology</i> , 2013, 4, 21.	1.6	161
69	Oncogenic extracellular vesicles in brain tumor progression. <i>Frontiers in Physiology</i> , 2012, 3, 294.	1.3	95
70	Cancer Cells Induced to Express Mesenchymal Phenotype Release Exosome-like Extracellular Vesicles Carrying Tissue Factor. <i>Journal of Biological Chemistry</i> , 2012, 287, 43565-43572.	1.6	130
71	Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. <i>Blood</i> , 2012, 119, 5543-5552.	0.6	176
72	Genetic pathways linking hemostasis and cancer. <i>Thrombosis Research</i> , 2012, 129, S22-S29.	0.8	35

#	ARTICLE	IF	CITATIONS
73	Extracellular vesicles – vehicles that spread cancer genes. <i>BioEssays</i> , 2012, 34, 489-497.	1.2	157
74	VEGF-D(ilated) Lymphatics as Gateways to Metastasis. <i>Cancer Cell</i> , 2012, 21, 139-140.	7.7	3
75	Age-related properties of the tumour vasculature in renal cell carcinoma. <i>BJU International</i> , 2011, 107, 416-424.	1.3	23
76	Microvesicles as mediators of intercellular communication in cancer – the emerging science of cellular debris™. <i>Seminars in Immunopathology</i> , 2011, 33, 455-467.	2.8	449
77	Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. <i>Blood</i> , 2010, 116, 815-818.	0.6	125
78	Microparticles in Cancer. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 888-906.	1.5	267
79	New technologies for the detection of circulating tumour cells. <i>British Medical Bulletin</i> , 2010, 94, 49-64.	2.7	103
80	Modulation of the oncogene-dependent tissue factor expression by kinase suppressor of ras 1. <i>Thrombosis Research</i> , 2010, 126, e6-e10.	0.8	22
81	Role of the tissue factor pathway in the biology of tumor initiating cells. <i>Thrombosis Research</i> , 2010, 125, S44-S50.	0.8	38
82	RAS Oncogenes and Tumor-Vascular Interface. , 2010, , 133-165.		2
83	Angiogenesis and Lymphangiogenesis in Colon Cancer Metastasis. <i>Cancer Metastasis - Biology and Treatment</i> , 2010, , 243-287.	0.1	1
84	Microvesicles: Messengers and mediators of tumor progression. <i>Cell Cycle</i> , 2009, 8, 2014-2018.	1.3	379
85	Tissue Factor and Cancer Stem Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 2005-2014.	1.1	40
86	Oncogene-Driven Hemostatic Changes in Cancer. <i>Cancer Investigation</i> , 2009, 27, 28-35.	0.6	2
87	Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3794-3799.	3.3	592
88	Tissue factor in tumour progression. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 71-83.	0.7	54
89	Vascular determinants of cancer stem cell dormancy – do age and coagulation system play a role?. <i>Apmis</i> , 2008, 116, 660-676.	0.9	26
90	Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. <i>Nature Cell Biology</i> , 2008, 10, 619-624.	4.6	1,688

#	ARTICLE	IF	CITATIONS
91	Contribution of Host-Derived Tissue Factor to Tumor Neovascularization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1975-1981.	1.1	79
92	Diverse Roles of Tissue Factor-Expressing Cell Subsets in Tumor Progression. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 170-181.	1.5	25
93	Tissue factor in cancer. <i>Current Opinion in Hematology</i> , 2008, 15, 522-528.	1.2	51
94	Tissue Factor and Cancer. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2007, 36, 160-176.	0.5	51
95	Atherosclerosis and Vascular Aging as Modifiers of Tumor Progression, Angiogenesis, and Responsiveness to Therapy. <i>American Journal of Pathology</i> , 2007, 171, 1342-1351.	1.9	33
96	The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. <i>Thrombosis Research</i> , 2007, 120, S82-S91.	0.8	43
97	Oncogenes, Trousseau Syndrome, and Cancer-Related Changes in the Coagulome of Mice and Humans. <i>Cancer Research</i> , 2006, 66, 10643-10646.	0.4	145
98	Is cancer stem cell a cell, or a multicellular unit capable of inducing angiogenesis?. <i>Medical Hypotheses</i> , 2006, 66, 601-604.	0.8	32
99	Tissue Factor in Cancer and Angiogenesis: The Molecular Link between Genetic Tumor Progression, Tumor Neovascularization, and Cancer Coagulopathy. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 054-070.	1.5	122
100	Oncogenes and Angiogenesis: Down-regulation of Thrombospondin-1 in Normal Fibroblasts Exposed to Factors from Cancer Cells Harboring Mutant Ras. <i>Cancer Research</i> , 2005, 65, 8878-8886.	0.4	60
101	Regulation of tissue factor and angiogenesis-related genes by changes in cell shape. <i>Biochemical and Biophysical Research Communications</i> , 2005, 337, 1267-1275.	1.0	16
102	Oncogenes as Regulators of Tissue Factor Expression in Cancer: Implications for Tumor Angiogenesis and Anti-Cancer Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 21-30.	1.5	51
103	Oncogenes and tumor angiogenesis. <i>Seminars in Cancer Biology</i> , 2004, 14, 93-104.	4.3	64
104	Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. <i>EMBO Journal</i> , 2003, 22, 4091-4102.	3.5	60
105	Oncogenes and Angiogenesis: Signaling Three-Dimensional Tumor Growth. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2000, 5, 24-33.	0.8	188
106	Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. <i>Cancer and Metastasis Reviews</i> , 2000, 19, 93-96.	2.7	48
107	Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. <i>Oncogene</i> , 1999, 18, 1023-1032.	2.6	71
108	The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor. <i>Angiogenesis</i> , 1998, 2, 203-217.	3.7	26